Assessment of bone status in inhaled corticosteroid user asthmatic patients with an ultrasound measurement method

Allergology International

Volumn 60, Issue 4, 2011, Pages 459-465

  Sasagawa, Mayumi ^a   Hasegawa, Takashi ^b   Kazama, Jun Ichiro J ^b   Koya, Toshiyuki ^b   Sakagami, Takuro ^b   Suzuki, Kazuo ^c   Hara, Katsuhito ^d   Satoh, Hideo ^e   Fujimori, Katsuya ^f   Yoshimine, Fumitoshi ^g   Satoh, Kazuhiro ^h   Narita, Ichiei ^b   Arakawa, Masaaki ^b   Gejyo, Fumitake ^b   Suzuki, Eiichi ^b  

^a Nanbugo Sogo Hospital   (Japan)

^b NIIGATA UNIVERSITY MEDICAL AND DENTAL HOSPITAL   (Japan)

^c Prefectural Muikamachi Hospital   (Japan)

^d Niigata Prefectural Yoshida Hospital   (Japan)

^e Nagaoka Chuo General Hospital   (Japan)

^f Niigata Prefectural Kamo Hospital   (Japan)

^g Prefectural Tsugawa Hospital   (Japan)

^h NAGAOKA RED CROSS HOSPITAL   (Japan)

Author keywords

Adult asthma; Adverse drug reaction; Asthma; Bone status; Inhaled corticosteroid

Indexed keywords

BECLOMETASONE; BUDESONIDE; CORTICOSTEROID; FLUTICASONE PROPIONATE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; THEOPHYLLINE;

ADULT; ARTICLE; ASTHMA; ATYPICAL MYCOBACTERIOSIS; BRONCHIECTASIS; CALCANEUS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DEPRESSION; DIABETES MELLITUS; DISEASE DURATION; DISEASE SEVERITY; DRUG EFFICACY; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; HUMAN; HYPERTENSION; MALE; NEUROSIS; PNEUMOCONIOSIS; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SARCOIDOSIS; SLEEP APNEA SYNDROME; TREATMENT RESPONSE; ULTRASOUND TRANSDUCER;

EID: 83455230688     PISSN: 13238930     EISSN: 14401592     Source Type: Journal    
DOI: 10.2332/allergolint.10-OA-0276     Document Type: Article

References (49)

1. Hoshino T, Toda R, Aizawa H. Pharmacological treatment in asthma and COPD. Allergol Int 2009;25:341-6.
2. National Institutes of Health; National Heart, Lung, and Blood Institute. National Asthma Education and Prevention Program. Expert Panel Report 3, 2007. Publication No. 07-4051. Available from: http://www.nhlbi.nih.gov/gu idelines/asthma/asthgdln.htm. Accessed December 30, 2007.
3. Monge RM, Montaner AE, Benitez MF et al. Consensus statement on the management of paediatric asthma. Allergol Immunopathol (Madr) 2006;34:88-101.
4. Hasegawa T, Suzuki E, Terada M et al. Improvement of asthma management in actual practice consistent with prevalence of anti-inflammatory agents.-Based on questionnaire surveys in Niigata Prefecture, Japan from 1998 to 2002-. Allergol Int 2005;54:555-63.
5. Hasegawa T, Suzuki E, Muramatsu Y et al. Questionnairebased analysis of the current level of asthma control and management in Niigata Prefecture, Japan: Changes from 1998 to 2000. Allergol Int 2004;53:135-44.
6. Irwin RS, Richardson ND. Side effects with inhaled corticosteroids: the physician's perception. Chest 2006;130: 41S-53.
7. Kelly HW, Nelson HS. Potential adverse effects of the inhaled corticosteroids. J Allergy Clin Immunol 2003;112: 469-78.
8. Buhl R. Local oropharyngeal side effects of inhaled corticosteroids in patients with asthma. Allergy 2006;61:518-26.
9. Kemp JP, Osur S, Shrewsbury SB et al. Potential effects of fluticasone propionate on bone mineral density in patients with asthma: a 2-year randomized, double-blind, placebo-controlled trial. Mayo Clin Proc 2004;79:458-66.
10. Li JT, Ford LB, Chervinsky P et al. Fluticasone propionate powder and lack of clinically significant effects on hypothalamic-pituitary-adrenal axis and bone mineral density over 2 years in adults with mild asthma. J Allergy Clin Immunol 1999;103:1062-8.
11. Medici TC, Grebski E, Häcki M, Rüegsegger P, Maden C, Efthimiou J. Effect of one year treatment with inhaled fluticasone propionate or beclomethasone dipropionate on bone density and bone metabolism: a randomised parallel group study in adult asthmatic subjects. Thorax 2000;55: 375-82.
12. Harmanci E, Colak O, Metintas M, Alatas O, Yurdasiper A. Fluticasone propionate and budesonide do not influence bone metabolism in the long term treatment of asthma. Allergol Immunopathol (Madr) 2001;29:22-7.
13. Tattersfield AE, Town GI, Johnell O et al. Bone mineral density in subjects with mild asthma randomised to treatment with inhaled corticosteroids or non-corticosteroid treatment for two years. Thorax 2001;56:272-8.
14. Luengo M, del Rio L, Pons F, Picado C. Bone mineral density in asthmatic patients treated with inhaled corticosteroids: a case-control study. Eur Respir J 1997;10: 2110-3.
15. Herrala J, Puolijoki H, Impivaara O, Liippo K, Tala E, Nieminen MM. Bone mineral density in asthmatic women on high-dose inhaled beclomethasone dipropionate. Bone 1994;15:621-3.
16. Nagasaka Y, Fujita E, Okawa K et al. [Effect of inhaled steroid on bone metabolism in the treatment of bronchial asthma]. Arerugi 1994;43:1398-404 (in Japanese).
17. Hughes JA, Conry BG, Male SM, Eastell R. One year prospective open study of the effect of high dose inhaled steroids, fluticasone propionate, and budesonide on bone markers and bone mineral density. Thorax 1999;54:223-9.
18. Matsumoto H, Ishihara K, Hasegawa T, Umeda B, Niimi A, Hino M. Effects of inhaled corticosteroid and short courses of oral corticosteroids on bone mineral density in asthmatic patients: a 4-year longitudinal study. Chest 2001; 120:1468-73.
19. Lipworth BJ. Systemic adverse effects of inhaled corticosteroid therapy: A systematic review and meta-analysis. Arch Intern Med 1999;10:941-55.
20. Sharma PK, Malhotra S, Pandhi P, Kumar N. Effect of inhaled steroids on bone mineral density: a meta-analysis. J Clin Pharmacol 2003;43:193-7.
21. Israel E, Banerjee TR, Fitzmaurice GM, Kotlov TV, La-Hive K, LeBoff MS. Effects of inhaled glucocorticoids on bone density in premenopausal women. N Engl J Med 2001;345:941-7.
22. Wong CA, Walsh LJ, Smith CJ et al. Inhaled corticosteroid use and bone-mineral density in patients with asthma. Lancet 2000;355:1399-403.
23. Sambrook PN. Inhaled corticosteroids, bone density, and risk of fracture. Lancet 2000;355:1385.
24. Ip M, Lam K, Yam L, Kung A, Ng M. Decreased bone mineral density in premenopausal asthma patients receiving long-term inhaled steroids. Chest 1994;105:1722-7.
25. Toogood JH, Baskerville JC, Markov AE et al. Bone mineral density and the risk of fracture in patients receiving long-term inhaled steroid therapy for asthma. J Allergy Clin Immunol 1995;96:157-66.
26. Hanania NA, Chapman KR, Sturtridge WC, Szalai JP, Kesten S. Dose-related decrease in bone density among asthmatic patients treated with inhaled corticosteroids. J Allergy Clin Immunol 1995;96:571-9.
27. Boulet LP, Milot J, Gagnon L, Poubelle PE, Brown J. Long-term influence of inhaled corticosteroids on bone metabolism and density. Are biological markers predictors of bone loss? Am J Respir Crit Care Med 1999;159: 838-44.
28. Liu H, Paige NM, Goldzweig CL et al. Screening for osteoporosis in men: a systematic review for an American College of Physicians guideline. Ann Intern Med 2008; 148:685-701.
29. Kanis JA. Diagnosis of osteoporosis and assessment of fracture risk. Lancet 2002;359:1929-36.
30. Sweet MG, Sweet JM, Jeremiah MP, Galazka SS. Diagnosis and treatment of osteoporosis. Am Fam Physician 2009;79:193-200.
31. Cauley JA, Thompson DE, Ensrud KC, Scott JC, Black D. Risk of mortality following clinical fractures. Osteoporos Int 2000;11:556-61.
32. Cummings SR, Bates D, Black DM. Clinical use of bone densitometry: scientific review. JAMA 2002;288:1889-97.
33. Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 1996;312:1254-9.
34. Kalkwarf HJ, Zemel BS, Gilsanz V et al. The Bone Mineral Density in Childhood Study (BMDCS): Bone mineral content and density according to age, sex and race. J Clin Endocrinol Metab 2007;92:2087-99.
35. Wu XP, Liao EY, Huang G, Dai RC, Zhang H. A comparison study of the reference curves of bone mineral density at different skeletal sites in native Chinese, Japanese, and American Caucasian women. Calcif Tissue Int 2003;73: 122-32.
36. Gonnelli S, Cepollaro C, Gennari L et al. Quantitative ultrasound and dual-energy X-ray absorptiometry in the prediction of fragility fracture in men. Osteoporos Int 2005; 16:963-8.
37. Karlsson MK, Duan Y, Ahlborg H, Obrant KJ, Johnell O, Seeman E. Age, gender, and fragility fractures are associated with differences in quantitative ultrasound independent of bone mineral density. Bone 2001;28:118-22.
38. He YQ, Fan B, Hans D et al. Assessment of a new quantitative ultrasound calcaneus measurement: precision and discrimination of hip fractures in elderly women compared with dual X-ray absorptiometry. Osteoporos Int 2000; 11:354-60.
39. Tsuda-Futami E, Hans D, Njeh CF et al. An evaluation of a new gel-coupled ultrasound device for the quantitative assessment of bone. Br J Radiol 1999;72:691-700.
40. Sasaki M, Harata S, Kumazawa Y, Mita R, Kida K, Tsuge M. Bone mineral density and osteo sono assessment in dex in adolescents. J Orthop Sci 2000;5:185-91.
41. Papapoulos SE, Quandt SA, Liberman UA, Hochberg MC, Thompson DE. Meta-analysis of the efficacy of alendronate for the prevention of hip fractures in postmenopausal women. Osteoporos Int 2005;16:468-74.
42. Cranney A, Wells G, Willan A et al; Osteoporosis Methodology Group and The Osteoporosis Research Advisory Group. Meta-analyses of therapies for postmenopausal osteoporosis. II. Meta-analysis of alendronate for the treatment of postmenopausal women. Endocr Rev 2002;23: 508-16.
43. Osteoporosis Prevention, Diagnosis, and Therapy. NIH Consensus Statement 2000; 17: 1-45. Available from: http://consensus.nih.gov/2000/2000Osteoporosis111html.htm.
44. Orimo S. [Osteoporosis Prevention and Management Guideline 2006]. Tokyo: Life Science Publishing, 2006 (in Japanese).
45. Nawata H, Soen S, Takayanagi R et al, and Subcommittee to Study Diagnostic Criteria for Glucocorticoid-Induced Osteoporosis. Guidelines on the management and treatment of glucocorticoid-induced osteoporosis of the Japanese Society for Bone and Mineral Research (2004). J Bone Miner Metab 2005;23:105-9.
46. Bauer DC, Gluer CC, Cauley JA et al. Broadband ultrasound attenuation predicts fractures strongly and independently of densitometry in older women. A prospective study. Study of Osteoporotic Fractures Research Group. Arch Intern Med 1997;157:629-34.
47. Schott AM, Hans D, Duboeuf F et al, and EPIDOS Study Group. Quantitative ultrasound parameters as well as bone mineral density are better predictors of trochanteric than cervical hip fractures in elderly women. Results from the EPIDOS study. Bone 2005;37:858-63.
48. Hasegawa T, Suzuki E, Koya T et al. Analysis of drug compliance in adult patients with bronchial asthma. Based on questionnaire surveys in Niigata Prefecture, Japan. General Med 2004;5:7-12.
49. Satoh H, Hasegawa T, Suzuki E et al. Gender differences in susceptibility of asthma to active smoking. Questionnaire based analysis in the Niigata Prefecture, Japan. Allergol Int 2005;54:401-10.